<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HAE207AC4101C4B71B9C7475159E7E8EB" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>110 HR 8289 IH: Banning Misleading Drug Ads Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-07-05</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8289</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220705">July 5, 2022</action-date><action-desc><sponsor name-id="S001209">Ms. Spanberger</sponsor> (for herself, <cosponsor name-id="W000826">Ms. Wild</cosponsor>, <cosponsor name-id="P000618">Ms. Porter</cosponsor>, <cosponsor name-id="C001119">Ms. Craig</cosponsor>, and <cosponsor name-id="A000378">Mrs. Axne</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Secretary of Health and Human Services to promulgate a past due final rule with respect to direct-to-consumer prescription drug advertisements, and for other purposes.</official-title></form><legis-body id="HDD734295C2724CED9DE7ABD8213403A5" style="OLC"><section id="HBE5F3022C2834118A8FF3F40CE9A9336" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Banning Misleading Drug Ads Act of 2022</short-title></quote>.</text></section><section id="HC359E87D17634DF4BA1E198AFB9B0C8A" section-type="subsequent-section"><enum>2.</enum><header>Past due final rule with respect to direct-to-consumer prescription drug advertisements</header><subsection id="H3B3F552D05454F6E940F7BDB01807529"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">If, by the date that is 180 days after the date of enactment of this Act, the Secretary of Health and Human Services has not promulgated a final rule establishing the standards required by section 901(d)(3)(B) of the Food and Drug Administration Amendments Act of 2007 (<external-xref legal-doc="public-law" parsable-cite="pl/110/85">Public Law 110â€“85</external-xref>), the proposed rule titled <quote>Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner</quote> (75 Fed. Reg. 15376 et seq.; March 29, 2010) is deemed to be a final rule and shall have effect beginning on such date.</text></subsection><subsection id="HD5A4F959DE8E4CC0A57333F85F77762F"><enum>(b)</enum><header>Rule of construction</header><text>Nothing in subsection (a) may be construed to prohibit the Secretary from promulgating, pursuant to the rulemaking authority of the Secretary under any other provision of law, a change to, including a replacement of, the rule deemed to be a final rule under such subsection.</text></subsection></section></legis-body></bill> 

